Blood tests predict dementia progression
- Trial ID
- NCT06529744
- Official Title
- Improving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling
- Goal
- Blood tests predict dementia progression
- Status
- RECRUITING
- Sponsor
- University Health Network, Toronto
- Study Type
- OBSERVATIONAL
- Enrollment
- 500 participants
- Conditions
- Dementia, Alzheimer Disease, Dementia With Lewy Bodies, Vascular Dementia, Frontotemporal Dementia, Mild Cognitive Impairment, Corticobasal Syndrome, Progressive Supranuclear Palsy, Parkinson Disease, Primary Progressive Aphasia
Plain-Language Summary
The goal is to improve how confidently clinicians can predict the course of Parkinson's and other neurodegenerative diseases that cause cognitive decline, so patients and families get clearer forecasts about progression and care needs. The approach is observational, gathering peripheral biomarkers like blood tests and other non-brain samples plus detailed clinical and cognitive assessments, then using integrative computational models to combine those signals and produce more accurate, individualized prognoses; it does not change your medical treatment. Adults 30 to 95 with possible or probable mild cognitive impairment or early dementia, who can consent, complete most study procedures, and have a study partner who sees them weekly are being sought.
Locations
- Baycrest, North York, Ontario, Canada
- Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada
- Toronto Western Hospital, University Health Network, Toronto, Ontario, Canada
- Centre for Addiction and Mental Health, Toronto, Ontario, Canada
Frequently Asked Questions
- What is this trial testing?
- This trial is studying an experimental treatment. The goal is to improve how confidently clinicians can predict the course of Parkinson's and other neurodegenerative diseases that cause cognitive decline, so patients and families get clearer forecasts about progression and care needs. The approach is observational, gathering peripheral biomarkers like blood tests and other non-brain samples plus detailed clinical and cognitive assessments, then using integrative computational models to combine those signals and produce more accurate, individualized prognoses; it does not change your medical treatment. Adults 30 to 95 with possible or probable mild cognitive impairment or early dementia, who can consent, complete most study procedures, and have a study partner who sees them weekly are being sought.
- Who can participate?
- Participants must be between 30 Years and 95 Years.
- Where is this trial located?
- This trial is recruiting at 4 locations.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 3 years.